CONTRAINDICATIONS AND PRECAUTIONS
Persons with a history of certain allergic disorders appear to have a greater risk for developing adverse reactions to JE vaccine. This history should be considered when weighing the risks and benefits of the vaccine for an individual patient. When patients with such a history are offered JE vaccine, they should be alerted to their increased risk for reaction and monitored appropriately. There are no data supporting the efficacy of prophylactic antihistamines or steroids in preventing JE vaccine-related allergic reactions.
Hypersensitivity to thimerosal is a contraindication to vaccination.
The vaccine should not be administered to persons who have had a previous adverse reaction after receiving JE vaccine. Patients who develop allergic or unusual adverse reactions after vaccination should be reported.
No data are available on the safety and efficacy of JE vaccine among infants <1 year of age. Whenever possible vaccination of infants should be deferred until they are 1 year of age or more.
No specific information is available on the safety of JE vaccine in pregnancy. Vaccination poses an unknown but theoretical risk to the developing fetus, and the vaccine should not be routinely administered during pregnancy. Pregnant women who must travel to an area where risk of JE is high should be vaccinated when the theoretical risks of immunization are outweighed by the risk of infection to the mother and developing fetus.
Simultaneous Administration of Other Vaccines or Drugs
Limited data suggest that the immunogenicity and safety of JE vaccination is not compromised by simultaneous administration with DTP vaccine. No data exist on the effect of concurrent administration of other vaccines, drugs (e.g., chloroquine, mefloquine), or biologicals on the safety and immunogenicity of JE vaccine.